.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The HORIZON trial provided randomized evidence that adding a Hydrus Microstent to cataract surgery can reduce intraocular pressure and medication burden. A five-year post hoc analysis examined visual-field progression, a more patient-important endpoint than pressure alone. The analysis compared eyes undergoing cataract surgery with or without Hydrus implantation and evaluated change in mean deviation over time. The work highlights an important principle in glaucoma care: lowering IOP is valuable because the ultimate goal is to preserve visual function, not simply achieve a laboratory target. The analysis also illustrates the difficulty of using visual-field progression as an endpoint because perimetric variability can obscure small changes over several years. For HCPs, the study supports monitoring both structure and function and interpreting visual-field trends longitudinally rather than from isolated tests. MIGS may be most attractive when it can meaningfully reduce medication burden while maintaining pressure control, particularly during cataract surgery. AIOC's glaucoma programme specifically addresses visual-field interpretation, OCT ganglion-cell assessment and MIGS, making this evidence highly relevant.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The HORIZON trial provided randomized evidence that adding a Hydrus Microstent to cataract surgery can reduce intraocular pressure and medication burden. A five-year post hoc analysis examined visual-field progression, a more patient-important endpoint than pressure alone. The analysis compared eyes undergoing cataract surgery with or without Hydrus implantation and evaluated change in mean deviation over time. The work highlights an important principle in glaucoma care: lowering IOP is valuable because the ultimate goal is to preserve visual function, not simply achieve a laboratory target. The analysis also illustrates the difficulty of using visual-field progression as an endpoint because perimetric variability can obscure small changes over several years. For HCPs, the study supports monitoring both structure and function and interpreting visual-field trends longitudinally rather than from isolated tests. MIGS may be most attractive when it can meaningfully reduce medication burden while maintaining pressure control, particularly during cataract surgery. AIOC's glaucoma programme specifically addresses visual-field interpretation, OCT ganglion-cell assessment and MIGS, making this evidence highly relevant.
last month
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
6 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
Last week
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
Last week
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
Last week
